Breast Cancer Prevention: Pregnancy Drug Breakthrough?

Abortion Drug shows Promise in Breast Cancer Prevention, Research Suggests

A medication primarily used for early pregnancy termination is attracting attention from researchers due to promising recent findings. Studies indicate it may reduce the proliferation of breast epithelium, a key factor in breast cancer growth, potentially offering a new preventative option for high-risk women.

Breast cancer is the most prevalent malignancy in women globally, responsible for approximately 670,000 deaths annually, according to the World Health association (WHO).

Blocking Progesterone, Blocking Cancer?

The drug, a synthetic steroid that blocks progesterone – a hormone crucial for maintaining pregnancy – is used in medication-based pregnancy interruptions. experts now believe it could help prevent breast cancer in women at elevated risk.

However, the drug’s association with abortion and resulting restrictions on access are hindering necessary research. Pharmaceutical companies are hesitant to fund clinical trials, despite three prior studies suggesting the drug’s potential to slow cancer cell development.

“Mifepristone could be useful in preventing breast cancer, but because it is associated with drug abortion and has restrictions on patents and regulations, research in this area has been blocked,” notes a group of scientists in a recent article published in The Lancet Obstetrics, Gynaecology and Women’s Health.

The authors, specialists in reproductive health and oncology from London, Edinburgh, Stockholm, and Erbil (Iraq), express disappointment that the drug’s triumphant submission in one medical field is impeding broader research for othre potentially life-saving indications.

Early Research shows Promise

Three previous studies – published in 2008,2022,and 2024 – provided evidence that the drug can limit the effects of progesterone,which stimulates cellular growth characteristic of breast cancer.

The stigma associated with this medicine used to interrupt pregnancy explains partially why it is not wider researched for the prevention of breast cancer.

kristina Gemzell Danielsson, lead author of the Lancet article and head of the department of Women and Child Health at the Karolinska institute in sweden, stated, “Our data, taken together, support its use to prevent breast cancer with unfavorable prognosis. All clinical studies have been randomized, in which low doses were administered for two months.”

The treatment is a selective progesterone receptor modulator. If proven effective, it could benefit women at high risk, such as those carrying BRCA1 or BRCA2 gene mutations, who currently face options like mastectomy or less effective drugs.

Urgent Need for Research

Experts emphasize the urgent need for new, less invasive treatments to help women at increased risk of breast cancer while preserving their quality of life. they stress the importance of considering all available options, including existing medications.

“It is indeed necessary for specialists to collaborate to accelerate studies to show whether the drug can be used as a non-surgical method to reduce the risk of breast cancer,” scientists urge.

Early studies have shown the drug slows cellular growth in breast tissue, potentially delaying or preventing cancer development. However, further research is needed to determine its effectiveness, mechanisms of action, and which patients would benefit most.

Cancer organizations in the UK have joined the call for prioritizing research into this medication as a potential breast cancer treatment.

The hope is that, by overcoming social and regulatory hurdles, this drug could become a life-saving option for millions of women worldwide. If clinical trials are successful and public support grows, it might very well be known not only as an abortion medication but also as a vital weapon against a widespread and deadly cancer.

References

• Bartlett, TE ∙ Evans, I ∙ Jones, A ∙ et al. Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome with. 2022; 14:64

• Engman, M ∙ skoog, L ∙ Söderqvist, G ∙ et al. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology.Hum Reprod. 2008; 23:2072-2079

• Utjés, d ∙ boggavarapu, nr ∙ rasul, mf ∙ et al. Transcriptomic profile of breast tissue of premenopausal women following treatment with progesterone receptor modulator: secondary outcomes of a randomized controlled trial.Int J Mol Sci. 2024; 257590